Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.

Clinical pharmacology and therapeutics - 1 Aug 2003

Werner Ulrike, Werner Dierk, Rau Thomas, Fromm Martin F, Hinz Burkhard, Brune Kay

Abstract excerpt

OBJECTIVE: In vitro data have shown that celecoxib inhibits the metabolism of cytochrome P450 (CYP) 2D6 substrates. However, very limited data are available on the influence of cyclooxygenase 2 inhibitors on the disposition of CYP2D6 substrates in humans. Therefore the objective of this study was to examine the effect of celecoxib and rofecoxib on the pharmacokinetics of the clinically relevant CYP2D6 substrate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Cyclooxygenase 2 Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclooxygenase Inhibitors

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Lactones

Share to Metoprolol

Share to Prostaglandin-Endoperoxide Synthases

Share to Sulfones

Source

Identifiers

PMID: 12891223
DOI: 10.1016/S0009-9236(03)00120-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.PMID 12891223Read ↗

Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.Semantic proximity Read ↗

The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.Semantic proximity Read ↗

Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry.Semantic proximity Read ↗

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.Semantic proximity Read ↗

Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.Semantic proximity Read ↗

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.Semantic proximity Read ↗

Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women.Semantic proximity Read ↗

Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.Semantic proximity Read ↗

Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.Semantic proximity Read ↗

Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.